|
|
|
|
| LEADER |
03139nam a22003855i 4500 |
| 001 |
000281527 |
| 005 |
20210720084042.0 |
| 007 |
cr nn 008mamaa |
| 008 |
130810s2013 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783642179075
|
| 024 |
7 |
|
|a 10.1007/978-3-642-17907-5
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 100 |
1 |
|
|a Klebe, Gerhard.
|e author.
|
| 245 |
1 |
0 |
|a Drug Design :
|b Methodology, Concepts, and Mode-of-Action /
|c by Gerhard Klebe.
|
| 250 |
|
|
|a 1st ed. 2013.
|
| 260 |
# |
# |
|a Berlin, Heidelberg :
|b Springer Berlin Heidelberg :
|b Imprint: Springer,
|c 2013.
|
| 300 |
|
|
|a 496 illus., 333 illus. in color. eReference. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Part I Fundamentalsin Drug Research -- 1. Drug Research Yesterday, Today and Tomorrow -- 2. The Role of Serendipityin Drug Research -- 3. Classical Drug Research -- 4. Protein–Ligand Interactionsas the Basis for Drug Action -- 5. Optical Activity and Biological Effects -- Part II Discovery and Optimizationof Lead Compounds -- 6. Screeningfor Lead Structures -- 7. Screening Technologies for LeadDiscovery -- 8. Optimizationof Lead Structures -- 9. Designingprodrugs -- 10. Peptidomimetics -- Part III Experimental and Theoretical Methods -- 11. Combinatorics: Chemistry With Big Numbers -- 12. Gene Technology in drug research -- 13. Experimental Methods of Structure Determination -- 14. The Spatial Structure of Biomolecules -- 15. Molecular Modelling -- 16. Conformational Analysis -- Part IV Structure–Activity Relationships and Design Approaches -- 17.Pharmacophore Hypothesis and Molecular Comparisons -- 18. Quantitative Structure–ActivityRelationships -- 19. From in vitro to in vivo:Optimization of ADME-Tox Properties -- 20. ProteinModeling and Structure-BasedDrug Design -- 21. ACase Study: Structure-Based Inhibtor Design for tRNA-Guanine Transglycosylase -- Part V. Drugs and drug action: Successes of stucture-based design -- 22. Howdrugs act: Concepts for therapy -- 23. Inhibitors of hydrolases With an acyl-enzymeintermediate -- 24. Asparticprotease inhibitors -- 25. Inhibitorsof hydrolysing metalloenzymes -- 26. Inhibitorsof transferases -- 27. Inhibitors ofoxidoreductases -- 28. Agonists and antagonistsof nuclear receptors -- 29. Agonists and antagonists of membrane-bound -- 30. Ligands forchannels, pores and transporters -- 31. Ligands for surfacereceptors -- 32. Biologicals: Peptides, proteins, nucleotidesand macrolides as drugs.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Pharmaceutical technology.
|
| 650 |
|
0 |
|a Medicinal chemistry.
|
| 650 |
|
0 |
|a Pharmacy.
|
| 650 |
1 |
4 |
|a Biomedicine, general.
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Pharmaceutical Sciences/Technology.
|
| 650 |
2 |
4 |
|a Medicinal Chemistry.
|
| 650 |
2 |
4 |
|a Pharmacy.
|
| 650 |
2 |
4 |
|a Medicine/Public Health, general.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer Nature eReference
|
| 900 |
|
|
|a Libro descargado a ALEPH en bloque (proveniente de proveedor)
|